Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Dysphagia, QoL and Attitudes Towards PEG in ALS Patients Primary and study completion pushed from Sep 30, 2026 to Dec 30, 2026 University Rehabilitation Institute, Republic of SloveniaNot specified NCT05336760
  2. Minor: Moisturization and Skin Hydration Study Primary completion pushed from Dec 2026 to May 2027 University of British ColumbiaNot applicable NCT07270965
  3. Minor: Robot-Aided Off-Axis Neuromuscular Training for Knee OA Primary completion pushed from Jun 1, 2029 to Oct 31, 2029 University of Maryland, BaltimoreNot applicable NCT07014098
  4. Minor: Use of AI Chatbots for Mental Health Primary completion pushed from Oct 2026 to Dec 2026 Medizinische Hochschule Brandenburg Theodor FontaneNot specified NCT07658547
  5. Minor: Extracorporeal Shock Wave Therapy, LASER Therapy and Cryotherapy in Patients Having Sacroiliitis Primary and study completion pushed from Sep 10, 2026 to Dec 10, 2026 Najran UniversityNot applicable NCT06569615
  6. Minor: Brief Mindfulness Training With Vagal Nerve Stimulation on Alcohol Cue Reactivity Among Young Adult Heavy Drinkers Primary and study completion pushed from Aug 2026 to Dec 31, 2026 Cambridge Health AllianceNot applicable NCT07516873
  7. Minor: 5 vs 8 cmH₂O PEEP on Respiratory Mechanics in Prone Lumbar Surgery Primary completion pushed from Sep 2, 2026 to Jan 31, 2027 Harran UniversityNot applicable NCT07545733
  8. Minor: Consciousness Studies and Cardiovascular Health Primary and study completion pushed from Oct 2028 to Dec 2028 University of MiamiNot applicable NCT07620639
  9. Minor: Ultrasound Detection of Body Composition in Critical Care Primary completion pushed from Oct 25, 2026 to Dec 25, 2026 Ain Shams UniversityNot specified NCT06728722
  10. Minor: Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Trial sites expanded: 4 → 7 locations GenmabPhase 3 NCT07775287
  11. Minor: EIK1001 in Combination With Pembrolizumab and Chemotherapy · Stage 4 Non-Small Cell Lung Cancer Trial sites expanded: 42 → 52 locations Eikon TherapeuticsPhase 2/3 NCT07365319
  12. Minor: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events Trial sites expanded: 252 → 261 locations AmgenPhase 3 NCT07136012
  13. Minor: ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Trial sites expanded: 6 → 9 locations Newave Pharmaceutical IncPhase 3 NCT07342478
  14. Minor: Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) Trial sites expanded: 124 → 129 locations Merck Sharp & Dohme LLCPhase 3 NCT07513376
  15. Minor: Inclisiran to Prevent Cardiovascular (CV) Events · Established Cardiovascular Disease Trial sites expanded: 983 → 989 locations Novartis PharmaceuticalsPhase 3 NCT05030428
  16. Minor: GSK5784283 (Felcorekibart) Compared With Placebo · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Trial sites expanded: 4 → 7 locations GlaxoSmithKlinePhase 3 NCT07782957
  17. Minor: Petrelintide · Overweight or Obesity and Established Cardiovascular Disease Trial sites expanded: 3 → 11 locations Hoffmann-La RochePhase 3 NCT07843472
  18. Minor: Fixed Doses of SEP-363856 · Generalized Anxiety Disorder Trial sites expanded: 17 → 27 locations Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3 NCT07759128
  19. Minor: Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment · Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Trial sites expanded: 34 → 69 locations GenmabPhase 3 NCT07225270
  20. Minor: Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Trial sites expanded: 7 → 12 locations Hoffmann-La RochePhase 2 NCT07781657
  21. Minor: NX-5948 · CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) Trial sites expanded: 43 → 47 locations Nurix Therapeutics, Inc.Phase 2 NCT07221500
  22. Minor: QCZ484 in Hypertensive Patients Trial sites expanded: 25 → 46 locations Novartis PharmaceuticalsPhase 2 NCT07543120
  23. Minor: ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy · AChR-Ab Seropositive Generalized Myasthenia Gravis Trial sites expanded: 14 → 19 locations argenxPhase 2 NCT07673627
  24. Minor: SRP-1005 · Huntington's Disease Trial sites expanded: 4 → 8 locations Sarepta Therapeutics, Inc.Phase 1 NCT07536061
  25. Minor: Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Trial sites expanded: 0 → 13 locations Merck Sharp & Dohme LLCNot specified NCT02653118